Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

Natural killer (NK) cells are key effectors in cancer immunosurveillance and posttransplant immunity, but deficiency of environmental signals and insufficient tumor recognition may limit their activity. We hypothesized that the antibody-mediated anchoring of interleukin-2 (IL-2) to a spliced isoform...

Full description

Bibliographic Details
Main Authors: Altvater, B. (Author), Angenendt, L. (Author), Berdel, A.F (Author), Berdel, W.E (Author), Bornhauser, M. (Author), Gerwing, M. (Author), Hartmann, W. (Author), Hemmerle, T. (Author), Hescheler, D. (Author), Kessler, T. (Author), Lenz, G. (Author), Matasci, M. (Author), Mikesch, J.-H (Author), Neri, D. (Author), Rollig, C. (Author), Rossig, C. (Author), Rueter, B. (Author), Ruhnke, L. (Author), Schafers, M. (Author), Scheller, A. (Author), Schliemann, C. (Author), Stelljes, M. (Author), Wermke, M. (Author), Wethmar, K. (Author)
Format: Article
Language:English
Published: American Society of Hematology 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items